Pipeline

The above pipeline chart reflects the status of Bristol-Myers Squibb compounds as of December 2007, and does not reflect any changes in status that may have occurred since that time.

Please click on product name to see the Full Prescribing Information for Abilify®, ATRIPLA™, Avapro®, Avalide®, Baraclude®, EMSAM®, ERBITUX®, IXEMPRA™, Orencia®, Plavix®, Reyataz®, SPRYCEL®, Sustiva®, and TAXOL®, including boxed WARNINGS for Abilify®, ATRIPLA™, Baraclude®, EMSAM®, ERBITUX®, IXEMPRA™, and TAXOL®, and boxed WARNINGS for Avapro® and Avalide® regarding use in pregnancy. As soon as pregnancy is detected, discontinue use of Avapro® and Avalide®.

¹Compounds in Exploratory Development are in preclinical or early clinical development.

²Full Development compounds are investigational drugs that are in late-stage clinical development or have been submitted to regulatory agencies for approval.

³Life Cycle Management compounds are among approved medicines that are driving current and future growth while continuing their clinical development to determine whether additional indications and formulations will benefit patients. Some Life Cycle Management compounds have been approved in one major market and are pending approval in other major markets. Current Life Cycle Management medicines include treatments in the areas of cardiovascular disease, HIV/AIDS, psychiatric disorders, rheumatoid arthritis, oncology and virology.

Like any other scientific endeavor, clinical testing of novel drug compounds is a complex time-consuming, resource-intensive process with no guaranteed results. But, as described here, Bristol-Myers Squibb is committed to pursuing such clinical development and, in doing so, to bringing new hope to patients.